Biocon spurts 3% as Pertuzumab drug moves closer to marketing nod in Europe

How 1 sources are covering this

• Business StandardCenter·1h ago

  Biocon spurts 3% as Pertuzumab drug moves closer to marketing nod in Europe

  Biocon jumped nearly 3% in Monday's trade after the company's Pertuzumab biosimilar drug received EMA CHMP recommendation for breast cancer care.

  Read at Business Standard →